At ALKemist Bio, we are developing novel immuno-therapies specifically designed to recognize the ALK oncogene—a known driver of several aggressive and treatment-resistant cancers. Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase normally active only during embryonic development, where it plays a role in the formation of the nervous system. In healthy adult tissues, ALK expression is minimal to absent. In cancer, ALK becomes aberrantly activated through genetic alterations such as: - Gene fusions (e.g., EML4–ALK), which lead to the expression of intracellular oncogenic fusion proteins - Point mutations, particularly in neuroblastoma - Gene amplification or overexpression, resulting in abnormal ALK signaling These alterations drive tumor growth and survival, making ALK a well-validated and highly specific target for precision therapies. Depending on the tumor type, ALK may be found either as an intracellular fusion protein or as a transmembrane receptor on the cell surface—a distinction that informs our therapeutic approach.